news
STING-activating drugs could customise cancer treatments
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
List view / Grid view
Metabolomics
news
Prize winner uncovers how microbiome can combat neurodegeneration
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
news
Genes behind antibiotic activity in bacteria uncovered by metabologenomics
Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
news
Bacterial metabolites could increase tumour therapy efficiency
Bacterial metabolites showed an increase in the cytotoxic activity in immune cells that could potentially influence efficiency of tumour therapies.
news
Metabolite could defend against harmful intestinal bacteria, study shows
Acetate was found to be involved in regulating complex microbes and could help trigger an immune response against harmful bacteria in mice.
news
High-throughput method developed for single-cell metabolic profiling
Scientists have presented a new method for generating the metabolic profiles of cells which could answer questions on conditions such as cancer and liver disease.
news
Small molecule to potentially treat diabetes discovered in screening study
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
news
Researchers visualise metabolic processes at the single-cell level
Scientists have used imaging methods and machine learning to understand cellular metabolism at the single-cell level.
webinar
Advantages of including untargeted and targeted metabolomics into drug development and clinical trials
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
news
New synthetic biologic could treat obesity-related diseases
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
news
Inhibiting Asc-1 protein function could present new drug target for obesity
Researchers have shown that loss of Asc-1 function could help obese patients maintain a healthy metabolism.
article
Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
news
Experimental mAb subdues type 1 diabetes in laboratory mice
A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
article
NOX5: a novel target for sensitising melanoma to therapies
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
news
CNS target could lead to development of drugs for diabetes
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
